Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher L Bowlus

Showing results (171-180 of 189) with videos related to

Pageof 19
Sort By:
Hepatology Communications|January 29, 2024
African American race does not confer an increased risk of clinical events in patients with primary sclerosing cholangitisMaryam Yazdanfar, Joseph Zepeda, Richard Dean, et al.
The American Journal of Gastroenterology|August 14, 2024
COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External ControlsKris V Kowdley, Gideon M Hirschfield, Charles Coombs, et al.
The American Journal of Gastroenterology|December 2, 2024
Correction to COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External ControlsKris V Kowdley, Gideon M Hirschfield, Charles Coombs, et al.
Journal of Hepatology|September 28, 2025
Phase II INTEGRIS-PSC trial of bexotegrast, an α<sub>v</sub>β<sub>6</sub>/α<sub>v</sub>β<sub>1</sub> integrin inhibitor, in primary sclerosing cholangitisGideon M Hirschfield, Kris V Kowdley, Palak J Trivedi, et al.
The New England Journal of Medicine|February 21, 2024
A Phase 3 Trial of Seladelpar in Primary Biliary CholangitisGideon M Hirschfield, Christopher L Bowlus, Marlyn J Mayo, et al.
Alimentary Pharmacology & Therapeutics|October 31, 2023
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitisMarlyn J Mayo, John M Vierling, Christopher L Bowlus, et al.
The Lancet. Gastroenterology & Hepatology|October 31, 2025
Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trialMichael Trauner, Cynthia Levy, Atsushi Tanaka, et al.
Journal of Hepatology|April 3, 2022
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitisChristopher L Bowlus, Michael R Galambos, Richard J Aspinall, et al.
The New England Journal of Medicine|November 14, 2023
Efficacy and Safety of Elafibranor in Primary Biliary CholangitisKris V Kowdley, Christopher L Bowlus, Cynthia Levy, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 19, 2020
Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing CholangitisCharlotte Rose Hawkey Hedin, Gina Sado, Nelson Ndegwa, et al.
Pageof 19

Showing results (171-180 of 189) with videos related to

Sort By:
Pageof 19
Hepatology Communications|January 29, 2024
African American race does not confer an increased risk of clinical events in patients with primary sclerosing cholangitisMaryam Yazdanfar, Joseph Zepeda, Richard Dean, et al.
The American Journal of Gastroenterology|August 14, 2024
COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External ControlsKris V Kowdley, Gideon M Hirschfield, Charles Coombs, et al.
The American Journal of Gastroenterology|December 2, 2024
Correction to COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External ControlsKris V Kowdley, Gideon M Hirschfield, Charles Coombs, et al.
Journal of Hepatology|September 28, 2025
Phase II INTEGRIS-PSC trial of bexotegrast, an α<sub>v</sub>β<sub>6</sub>/α<sub>v</sub>β<sub>1</sub> integrin inhibitor, in primary sclerosing cholangitisGideon M Hirschfield, Kris V Kowdley, Palak J Trivedi, et al.
The New England Journal of Medicine|February 21, 2024
A Phase 3 Trial of Seladelpar in Primary Biliary CholangitisGideon M Hirschfield, Christopher L Bowlus, Marlyn J Mayo, et al.
Alimentary Pharmacology & Therapeutics|October 31, 2023
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitisMarlyn J Mayo, John M Vierling, Christopher L Bowlus, et al.
The Lancet. Gastroenterology & Hepatology|October 31, 2025
Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trialMichael Trauner, Cynthia Levy, Atsushi Tanaka, et al.
Journal of Hepatology|April 3, 2022
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitisChristopher L Bowlus, Michael R Galambos, Richard J Aspinall, et al.
The New England Journal of Medicine|November 14, 2023
Efficacy and Safety of Elafibranor in Primary Biliary CholangitisKris V Kowdley, Christopher L Bowlus, Cynthia Levy, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 19, 2020
Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing CholangitisCharlotte Rose Hawkey Hedin, Gina Sado, Nelson Ndegwa, et al.
Pageof 19